Vanda Pharmaceuticals to Present Data on Iloperidone at the 2007 American Psychiatric Association Annual Meeting

May 18, 2007

ROCKVILLE, Md., May 18 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced today that it will present four posters on iloperidone at the 160th American Psychiatric Association (APA) annual meeting which will be held at the San Diego Convention Center in San Diego, CA, from May 19 through May 24, 2007.

The following posters will be presented on May 22, 2007, 12:00 to 2:00 p.m. PDT, in the San Diego Convention Center (Sails Pavilion, Upper Level).

POSTER NR475 - Changes in Akathisia with Iloperidone, Risperidone, or Placebo Over the Course of an Acute Efficacy Trial (Peter Weiden, M.D. and Curt Wolfgang, Ph.D.)

POSTER NR476 - Iloperidone is Well Tolerated by Subjects with Renal or Hepatic Impairment in Single-Dose Clinical Pharmacokinetic Studies (Greg Sedek, M.D., Ph.D. and Curt Wolfgang, Ph.D.)

POSTER NR507 - A Pharmacokinetic (PK)-Pharmacodynamic (PD) Relationship Exists for Efficacy of Iloperidone, a Novel Investigational Atypical Antipsychotic Agent (Paolo Baroldi, M.D., Ph.D. and Curt Wolfgang, Ph.D.)

POSTER NR508 - Genotyping Facilitates Individualized Prediction of Pharmacokinetic Exposure of Iloperidone in Extensive and Poor CYP2D6 Metabolizers (Curt Wolfgang, Ph.D.)

ABOUT VANDA PHARMACEUTICALS INC.: 

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. The company has three product candidates in clinical development. Vanda’s lead product candidate, iloperidone, is a compound for the treatment of schizophrenia and bipolar disorder and has recently completed its Phase III program in schizophrenia. Vanda’s second product candidate, VEC-162, is a compound for the treatment of sleep and mood disorders which is currently in Phase III for insomnia. Vanda’s third product candidate, VSF-173, is a compound for the treatment of excessive sleepiness that is in a Phase II clinical trial. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com.

SOURCE Vanda Pharmaceuticals Inc.